3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Glioblastoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gliosarcoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
87
Paclitaxel
77
Bevacizumab
38
Topotecan
23
liposomal doxorubicin
22
Gemcitabine
22
Taxes
21
Cisplatin
17
Drug Therapy
14
Docetaxel
14
Cyclophosphamide
14
pembrolizumab
13
Immunoglobulin G
12
Disulfides
12
veliparib
8
rucaparib
8
mirvetuximab soravtansine
8
niraparib
7
Albumin-Bound Paclitaxel
7
sargramostim
6
Filgrastim
6
Erlotinib Hydrochloride
6
Doxorubicin
6
pazopanib
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Chemotherapy, Adjuvant
5
CP protocol
5
trebananib
4
temsirolimus
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Fallopian Tube Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts